 MARIETTA, Ga., Sept. 08, 2021 GLOBE NEWSWIRE -- MiMedx Group, Inc. Nasdaq: MDXG MIMEDX or the Company, an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the shelf registration statement on Form S-3 on file with the Securities and Exchange Commission SEC has become effective. The shelf registration statement allows the Company to sell up to 350 million of various types of securities over the next three years. 